Glioblastoma is the most common primary malignant brain tumour. Survival is poor and
improved treatment options are urgently needed. Although immunotherapies have emerged …

Glioblastoma is the most common and aggressive primary malignant brain tumour. The
prognosis of patients with glioblastoma is poor, and their overall survival averages at 1 year …

The different drugs and medical devices, which are commercialized or under industrial
development for glioblastoma treatment, are reviewed. Their different modes of action are …

The development of immunotherapies has revolutionized intervention strategies for a variety
of primary cancers. Despite this promising progress, treatment options for primary brain …

Background Glioblastoma, or glioblastoma multiforme (GBM), remains a fatal cancer type
despite the remarkable progress in understanding the genesis and propagation of the tumor …

Central nervous system disorders, especially neurodegenerative diseases, are a public
health priority and demand a strong scientific response. Various therapy procedures have …

Gliomas are the most prevalent primary malignant brain tumors associated with poor
prognosis. NAMPT, a rate-limiting enzyme that boosts the nicotinamide adenine …

Glioblastoma (GBM) is a highly aggressive primary brain tumor that is largely refractory to
treatment and, therefore, invariably relapses. GBM patients have a median overall survival of …

Glioblastoma multiforme is a serious medical issue in the brain oncology field due to its
aggressiveness and recurrence. Immunotherapy has emerged as a valid approach to …

Inhibiting epigenetic modulators can transcriptionally reactivate transposable elements
(TEs). These TE transcripts often generate unique peptides that can serve as immunogenic …